Skip to main content
SpringerLink
Log in
Book cover

Cell Injury and Protection in the Gastrointestinal Tract pp 175–185Cite as

The Role of Cysteine and Serine Proteases in Gastric Carcinogenesis and Their Prognostic Impact in Gastric Cancer

  • Chapter

  • 91 Accesses

Abstract

Cysteine proteases (cathepsin B [CATB], cathepsin L [CATL], the serine protease urokinase-type plasminogen activator (UPA) and its inhibitor PAI-1 play an important part in cancer invasion. Little is known about their prognostic value in gastric cancer and no data are available on the possible relationship between these proteases and gastric precancerous changes.

Aims:

  1. 1.

    To determine CATB, CATL, UPA, PAI-1 in chronic atrophic gastritis with intestinal metaplasia and in gastric epithelial dysplasia — as precancerous changes — in gastric cancer and in cancer-free mucosa;

  2. 2.

    To evaluate their prognostic value with respect to survival in gastric cancer.

Samples of tumour and of normal mucosa were obtained from 25 patients undergoing gastrectomy. Biopsies were taken from 33 patients with chronic atrophic gastritis (12 with dysplasia) and from 47 control subjects. Antigen concentrations were measured using ELISA Survival was analysed by Cox’s model.

CATB, CATL, UPA and PAI-1 were significantly higher in cancer vs. cancer-free tissue. Chronic atrophic gastritis showed intermediate values between cancer and non-cancerous tissue. CATB and UPA were significantly higher in chronic atrophic gastritis with vs. without dysplasia. Low UPA, PAI-1 and CATB were associated with better survival. These proteases and PAI-1 have a role, not only in cancer invasion, but also in the progression of precancerous changes into cancer and have a strong prognostic impact.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nigam AK, Pignatelli M, Boulos PB. Current concepts in metastasis. Gut, 1994;35:996–1000.

    Article  PubMed  CAS  Google Scholar 

  2. Mason RW, Johnson DA, Barrett AJ, Chapman HA. Elastinolytic activity of human cathepsin L. Biochem J. 1986;233:925–7.

    PubMed  CAS  Google Scholar 

  3. Okoda Y, Yokota Y. Purification and properties of cathepsin B from sea urchin eggs. Comp Biochem Physiol. 1990; 96: 3 81–6.

    Google Scholar 

  4. Sloane BF. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol. 1990;1:137–52.

    PubMed  CAS  Google Scholar 

  5. Ohta T, Terada T, Nagakawa T et al. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer. 1994;69:152–6.

    Article  PubMed  CAS  Google Scholar 

  6. Shuja S, Sheahan K, Murnane MJ. Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int J Cancer. 1991;49:341–6.

    Article  PubMed  CAS  Google Scholar 

  7. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Shiver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 1985;44:139–266.

    Article  PubMed  CAS  Google Scholar 

  8. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Ann Rev Cell Biol. 1988;4:93–126.

    Article  PubMed  CAS  Google Scholar 

  9. Markus G. The relevance of plasminogen activators to neoplastic growth - a review of recent literature. Enzyme. 1988;40:158–72.

    PubMed  CAS  Google Scholar 

  10. Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, Takada A. The urokinase type of plasminogen activator in cancer of digestive tract. Thromb Res. 1988;50:527–35.

    Article  PubMed  CAS  Google Scholar 

  11. Hart IR, Saini A. Biology of tumor metastasis. Lancet. 1992;339:1453–7.

    Article  PubMed  CAS  Google Scholar 

  12. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381–7.

    PubMed  CAS  Google Scholar 

  13. Janicke F, Schmitt M, Pache L et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24:WE.

    Google Scholar 

  14. Bouchet C, Spyratos F, Martin PM, Hacéne K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (UPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer. 1994;69:398–405.

    Article  PubMed  CAS  Google Scholar 

  15. Landau BJ, Kwaan HC, Verrusio EN, Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 in malignant human brain tumors. Cancer Res. 1994;54:1105–8.

    PubMed  CAS  Google Scholar 

  16. Sier CFM, Verspaget HW, Griffioen G et al. Inbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implication of urokinase in colorectal carcinogenesis. Gastroenterology. 1991;101:1522–8.

    PubMed  CAS  Google Scholar 

  17. Kirchheimer JC, Huber K, Wagner O, Binder BR. Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol. 1987;66:85–9.

    Article  PubMed  CAS  Google Scholar 

  18. Tanaka N, Fukao H, Ueshima S, Okada K, Yasutomi M, Matsuo O. Plasminogen activator inhibitor 1 in human carcinoma tissues. Int J Cancer. 1991;48:481–4.

    Article  PubMed  CAS  Google Scholar 

  19. Buo L, Lyberg T, Jorgensen L, Johansen HT, Aasen AO. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. APMIS. 1993;101:235–41.

    Article  PubMed  CAS  Google Scholar 

  20. Sier CFM, Vloedgraven HJM, Ganesh S et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology. 1994;107:1449–56.

    PubMed  CAS  Google Scholar 

  21. Vasishta A, Baker PR, Hopwood D, Holley PM, Cuschieri A. Proteinase-like peptidase activities in malignant and non-malignant gastric tissue. Br J Surg. 1985;72:386–8.

    Article  PubMed  CAS  Google Scholar 

  22. Watanbe M, Higashi T, Watanabe A et al. Cathepsin B and L activities in gastric cancer tissue: correlation with histological findings. Biochem Med Metab Biol. 1989;42:21–9.

    Article  Google Scholar 

  23. Chung SM, Kawai K. Protease activities in gastric cancer tissues. Clin Chim Acta. 1990;189:205–10.

    Article  PubMed  CAS  Google Scholar 

  24. Takai S, Yamamura M, Tanaka K et al. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer. 1991;48:20–7.

    Article  PubMed  CAS  Google Scholar 

  25. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJM, Lamers CBHW. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut. 1993;34:80–5.

    Article  PubMed  CAS  Google Scholar 

  26. Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 1994;54:2900–7.

    PubMed  CAS  Google Scholar 

  27. Plebani M, Herszényi L, Cardin R et al. Cysteine and serine proteases in gastric cancer. Cancer. 1995;76:367–75.

    Article  PubMed  CAS  Google Scholar 

  28. De Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Lamers CBHW. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps and adenocarcinomas. Cancer Res. 1987;47:4654–7.

    PubMed  Google Scholar 

  29. Farinati F, Plebani M, Di Mario F et al. Aspartic proteinases and gastrin in the diagnosis of gastric cancer and gastric precancerous changes. Eur J Gastroenterol Hepatol. 1993;5:707–12.

    Article  Google Scholar 

  30. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationship among serum pepsinogen I, pepsinogen II, and gastric mucosal history. Gastroenterology. 1982;83:204–9.

    PubMed  CAS  Google Scholar 

  31. Mild K, Ichinose M, Ishikawa KB et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res. 1993;84:1086–90.

    Article  Google Scholar 

  32. Matsukura N, Onda M, Tokunaga A et al. Significance of serum markers pepsinogen I and II for chronic atropic gastritis, peptic ulcer and gastric cancer. J Clin Gastroenterol. 1993;17:146–50.

    Article  Google Scholar 

  33. Rugge M, Baffa R, Farinati F et al. Epithelial dysplasia in atrophic gastritis. Bioptical follow-up study. Ital J Gastroenterol. 1991;23:70–3.

    PubMed  CAS  Google Scholar 

  34. Correa P. Chronic gastritis: a clinicopathologic classification. Am J Gastroenterol. 1988;83:504–9.

    PubMed  CAS  Google Scholar 

  35. Price AB. The Sydney system. J Gastroenterol Hepatol. 1991;6:209–22.

    Article  PubMed  CAS  Google Scholar 

  36. Morson BC, Sobin LH, Grundmann E, Johansen A, Nagayo T, Serck-Hanssen A. Precancerous conditions and epithelial dysplasia in the stomach. J Clin Pathol. 1980;33:711–21.

    Article  PubMed  CAS  Google Scholar 

  37. Riddel RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Hum Pathol. 1983;14:9331–68.

    Google Scholar 

  38. Bradford MA. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.

    Article  PubMed  CAS  Google Scholar 

  39. Wodzinski MA, Bardhan KD, Reilly JT, Cooper P, Preston FE. Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease. Gut. 1993;34:1310–4.

    Article  PubMed  CAS  Google Scholar 

  40. Nitti D, Farini R, Grassi F et al. Carcinoembryonic antigen in gastric cancer juice collected during endoscopy. Value in detecting high-risk patients and gastric cancer. Cancer. 1984;52:2334–7.

    Article  Google Scholar 

  41. Farinati F, Nitti D, Cardin F et al. CA 19–9 determination in gastric juice: role in identifying cancer and high-risk patients. Eur J Cancer Clin Oncol. 1988;24:923–7.

    Article  PubMed  CAS  Google Scholar 

  42. Farinati F, Holmgren J, Di Mario F et al. CA 50 determination in body fluids: can we screen patients at risk for gastric cancer? Int J Cancer. 1991;47:7–11.

    Article  PubMed  CAS  Google Scholar 

  43. Saku T, Sakai H, Tsuda N, Okabe H, Kato Y, Yamamoto K. Cathepsin D and E in normal, metaplastic, dysplastic, and carcinomatous gastric tissue: an immunohistochemical study. Gut. 1990;31:1250–5.

    CAS  Google Scholar 

  44. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48:3554–60.

    PubMed  CAS  Google Scholar 

  45. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.

    PubMed  CAS  Google Scholar 

  46. Sipponen P, Kekki M, Siurala M. Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Cancer. 1983;52:1062–8.

    Article  PubMed  CAS  Google Scholar 

  47. Farinati F, Cardin F, Di Mario F et al. Follow-up in gastric dysplasia patients. Am J Surg Pathol. 1989;13:173–4.

    Article  PubMed  CAS  Google Scholar 

  48. Rugge M, Farinati F, Di Mario F, Baffa R, Valiante F, Cardin F. Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia. Hum Pathol. 1991;22:1002–8.

    Article  PubMed  CAS  Google Scholar 

  49. Farinati F, Rugge M, Di Mario F, Valiante F, Baffa R. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. Endoscopy. 1993;25:261–4.

    Article  PubMed  CAS  Google Scholar 

  50. Rugge M, Farinati F, Baffa R et al. Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Gastroenterology. 1994;107:1288–96.

    PubMed  CAS  Google Scholar 

  51. Ming SC, Bajtai A, Correa P et al. Gastric dysplasia: significance and pathologic criteria. Cancer. 1984;54:1794–801.

    Article  PubMed  CAS  Google Scholar 

  52. Lansdown M, Quirke P, Dixon MF, Axon AT, Johnston D. High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut. 1990;31:977–80.

    Article  PubMed  CAS  Google Scholar 

  53. De Dombal FT, Price AB, Thompson H et al. The British Society of Gastroenterology early gastric cancer/dysplasia survey: an interim report. Gut. 1990;31:115–20.

    Article  PubMed  Google Scholar 

  54. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pathol. 1994;144:511–17.

    PubMed  CAS  Google Scholar 

  55. Correa P, Shiao Y. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res. 1994; 54(Suppl):1941–3.

    Google Scholar 

  56. Reilly D, Christensen L, Duch M, Nolan N, Duff MJ, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer. 1992;50:208–14.

    Article  PubMed  CAS  Google Scholar 

  57. Kristensen P, Pyke C, Lund LR, Andreasen PA, Dano K. Plasminogen activator inhibitor type-1 in Lewis lung carcinoma. Histochemistry. 1990;93:559–66.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary

    L. Herszényi & Z. Tulassay

  2. Cattedra Malattie Apparato Digerente, Istituto di Medicina Interna, Italy

    F. Farinati & R. Naccarato

  3. Dipartimento di Medicina di Laboratorio, Laboratorio Centrale, Universitá di Padova, Italy

    M. Plebani, P. Carraro, M. De Paoli & G. Roveroni

Authors
  1. L. Herszényi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Farinati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Plebani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Carraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. De Paoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Roveroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Naccarato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Z. Tulassay
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pécs, Hungary

    Gy. Mózsik , L. Nagy  & A. Pár ,  & 

  2. Sheffield, UK

    K. D. Rainsford

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Herszényi, L. et al. (1997). The Role of Cysteine and Serine Proteases in Gastric Carcinogenesis and Their Prognostic Impact in Gastric Cancer. In: Mózsik, G., Nagy, L., Pár, A., Rainsford, K.D. (eds) Cell Injury and Protection in the Gastrointestinal Tract. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5392-8_18

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5392-8_18

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6268-8

  • Online ISBN: 978-94-011-5392-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation